| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Feb, 2026 | Feb, 2026 |
| Sales | 134,350 | 30,550 | 31,170 | 0 | 0 |
| Sales Growth | +339.77% | -1.99% | unch | unch | unch |
| Net Income | -55,540 | -127,370 | -131,220 | 0 | 0 |
| Net Income Growth | +56.39% | +2.93% | unch | unch | unch |
Ascentage Pharma Group Intl ADR
(AAPG)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Ascentage Pharma is an integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address unmet medical needs primarily in hematological malignancies. Ascentage Pharma is based in ROCKVILLE, Md.
Fiscal Year End Date: 12/31